Skip to main content

Table 1 Study characteristics

From: Comparative safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis

Characteristic Number of studiesa (n = 115) Percentage of studies (%)
Year of publication  
1990–1994 7 6.1
1995–1999 37 32.2
2000–2004 19 16.5
2005–2009 36 31.3
2010–2013 16 13.9
Geographic region  
Europe 42 36.5
North America 30 26.1
Asia 28 24.3
Multi-continent 8 7.0
Australasia 3 2.6
Africa 2 1.7
Not reported 1 0.9
South America 1 0.9
Study design  
Randomized clinical trial 112 97.4
Non-randomized clinical trial 2 1.7
Controlled before–after study 1 0.9
Study conduct period   
1990–1999 1 0.9
2000–2009 15 13.0
2010–2013 1 0.9
Not reported 98 85.2
Duration of follow-up b  
0 to ≤6 9 7.8
>6 to ≤12 2 1.7
>12 to ≤24 79 68.7
>24 to ≤48 17 14.8
>48 to ≤72 2 1.7
>72 to ≤1 week 3 2.6
Not reported 3 2.6
Interventions examined: frequency c   
Serotonin antagonists: Reported as administered alone (administered with dexamethasone)
Ondansetron 79 (7) 68.70 (6.1)
Granisetron 14 (4) 12.2 (3.5)
Tropisetron 15 (0) 13.0 (0.0)
Dolasetron 15 (1) 13.0 (0.9)
Palonosetron 4 (0) 3.5 (0.0)
Ramosetron 3 (1) 2.6 (0.9)
Comparator antiemetics:
Butyrophenone 26 22.61
Benzamide 14 12.17
Dexamethasone 6 5.2
Phenothiazine 2 1.7
Antihistamine 3 2.61
NK-1 4 3.5
Anticholinergic 0 0
Serotonin antagonists given with other antiemetic:
Serotonin antagonist + dexamethasone 13 11.3
Serotonin antagonist + butyrophenone 5 4.4
Serotonin antagonist + benzamide 0 0
Serotonin antagonist + antihistamine 1 0.9
Serotonin antagonist + NK-1 1 0.9
Serotonin antagonist + phenothiazine 0 0
Placebo or no treatment 86 74.78
Outcomes examined: frequency d   
Arrhythmia 53 46.1
Delirium 34 29.6
Mortality 28 24.3
QT prolongation 18 15.7
Setting  
Not reported 71 61.7
Hospital 25 21.7
Medical center 16 13.9
Multi-center 3 2.6
  1. aIncludes unpublished data [84]; bduration is in hours unless otherwise noted; cmultiple interventions and comparators examined across the studies; dmultiple interventions and outcomes reported per study. NK-1: Neurokinin 1 receptor antagonist